Literature DB >> 29724422

ACR Appropriateness Criteria® Staging and Follow-Up of Ovarian Cancer.

Stella K Kang1, Caroline Reinhold2, Mostafa Atri3, Carol B Benson4, Priyadarshani R Bhosale5, Anuja Jhingran5, Yulia Lakhman6, Katherine E Maturen7, Refky Nicola8, Pari V Pandharipande9, Gloria M Salazar9, Thomas D Shipp10, Lynn Simpson11, William Small12, Betsy L Sussman13, Jennifer W Uyeda4, Darci J Wall14, Bradford P Whitcomb15, Carolyn M Zelop16, Phyllis Glanc17.   

Abstract

In the management of epithelial ovarian cancers, imaging is used for cancer detection and staging, both before and after initial treatment. The decision of whether to pursue initial cytoreductive surgery for ovarian cancer depends in part on accurate staging. Contrast-enhanced CT of the abdomen and pelvis (and chest where indicated) is the current imaging modality of choice for the initial staging evaluation of ovarian cancer. Fluorine-18-2-fluoro-2-deoxy-d-glucose PET/CT and MRI may be appropriate for problem-solving purposes, particularly when lesions are present on CT but considered indeterminate. In patients who achieve remission, clinical suspicion for relapse after treatment prompts imaging evaluation for recurrence. Contrast-enhanced CT is the modality of choice to assess the extent of recurrent disease, and fluorine-18-2-fluoro-2-deoxy-d-glucose PET/CT is also usually appropriate, as small metastatic foci may be identified. If imaging or clinical examination confirms a recurrence, the extent of disease and timing of disease recurrence then determines the choice of treatments, including surgery, chemotherapy, and radiation therapy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2018 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; Imaging evaluation; Ovarian cancer; Recurrence; Staging

Mesh:

Substances:

Year:  2018        PMID: 29724422     DOI: 10.1016/j.jacr.2018.03.015

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  4 in total

1.  Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.

Authors:  Elizabeth A Sadowski; Atul B Shinagare; Hyesun Park; Olga R Brook; Rosemarie Forstner; Sumer K Wallace; Jeanne M Horowitz; Neil Horowitz; Marcia Javitt; Priyanka Jha; Aki Kido; Yulia Lakhman; Susanna I Lee; Lucia Manganaro; Katherine E Maturen; Stephanie Nougaret; Liina Poder; Gaiane M Rauch; Caroline Reinhold; Evis Sala; Isabelle Thomassin-Naggara; Herbert Alberto Vargas; Aradhana Venkatesan; Olivera Nikolic; Andrea G Rockall
Journal:  Eur Radiol       Date:  2021-11-30       Impact factor: 7.034

Review 2.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

Review 3.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

Review 4.  Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Authors:  Abdulaziz Babaier; Hanan Mal; Waleed Alselwi; Prafull Ghatage
Journal:  Diagnostics (Basel)       Date:  2022-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.